{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-019022","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.307834+00:00","generated_at":"2026-06-18T05:37:42.404836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Longeveron Q4 net loss $4.5M, FY 2022 loss $18.8M; cash $19.6M, runway into H1 2024","bullets":["Q4 2022 net loss $4.5M ($0.21/share) vs $4.1M; full year loss $18.8M ($0.90/share) vs $17.0M.","Revenue Q4 $0.1M, full year $1.2M (flat vs $1.3M); clinical trial revenue up 29% to $0.9M.","Cash and short-term investments $19.6M at Dec 31, 2022, down from $35.0M; funds operations into H1 2024.","Completed enrollment in Phase 2a Alzheimer's trial (CLEAR MIND, 48 patients); topline results expected early 2024.","Initiated Phase 2 Aging-Related Frailty trial in Japan; first patient randomization expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-019022","json":"https://secwatch.observer/filing/0001213900-23-019022.json","markdown":"https://secwatch.observer/filing/0001213900-23-019022.md","text":"https://secwatch.observer/filing/0001213900-23-019022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023019022/0001213900-23-019022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023019022/ea175011-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:37:42.404836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c35dfabeae74a6d7a7b6229155a2217225495b45","claim":"Longeveron Inc. reported fourth quarter and full year of 2022 results: revenue Revenue in the fourth quarter 2022 was $0.1 million compared to $0.2 million in the same period in 2021. Revenue for ful, net income Net loss was $4.5 million in the fourth quarter of 2022 compared to $4.1 million for the same period in 2021. Net loss f.","evidence_excerpt":"On March 10, 2023, the Company announced financial and operating results as of and for the three and twelve months ended December 31, 2022 and 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023019022/0001213900-23-019022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year of 2022"},{"label":"Revenue","value":"Revenue in the fourth quarter 2022 was $0.1 million compared to $0.2 million in the same period in 2021. Revenue for ful"},{"label":"Net income","value":"Net loss was $4.5 million in the fourth quarter of 2022 compared to $4.1 million for the same period in 2021. Net loss f"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}